EGFR and glioblastoma: The current WHO 2021 classification scheme now recognizes that the diagnosis of glioblastoma can be established in an IDH-wt diffuse astrocytic neoplasm either on basis of histologic features (microvascular proliferation and/or necrosis) or molecular features (TERTp mutation, EGFR amplification, or chromosome + 7/-10) [3].